Repligen Corporation
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-95.3% vs price
Base Case (Median)
-87.9% vs price
Bull Case (75th pct.)
-83.4% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-10.74 | -106.4% | High (40%) |
| PE Comparable | $16.25 | -90.4% | Medium (25%) |
| Graham Number | $24.80 | -85.3% | Medium (40%) |
| EV/EBITDA | $29.22 | -82.7% | Medium (20%) |
| EV/FCF | $39.40 | -76.7% | Medium (20%) |
| Earnings Power Value | $5.27 | -96.9% | Medium (50%) |
Based on 6 out of 8 methods, RGEN appears overvalued at the current price of $169.04. The base case fair value of $20.52 implies 87.9% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.